Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.

Company Overview and News

Leading Proxy Advisory Firms Reject Terminated CEO’s Attempt to Retake Control of Alexandria Minerals

2018-07-13 globenewswire
TORONTO, July 13, 2018 (GLOBE NEWSWIRE) -- Alexandria Minerals Corporation (TSX-V:AZX) (OTCQB:ALXDF) (Frankfurt:A9D) (“AZX” or the “Company”) announces that leading independent proxy advisory firms Institutional Shareholder Services Inc. ("ISS") and Glass Lewis & Co. ("Glass Lewis") recommended that the Company's shareholders vote FOR all of management’s resolutions at its special meeting of shareholders (the “Meeting”) on July 24, 2018.

New Alexandria Minerals Letter Urges Shareholders to Vote the BLUE Proxy Today for a New Corporate Direction

2018-07-09 globenewswire
TORONTO, July 09, 2018 (GLOBE NEWSWIRE) -- Alexandria Minerals Corporation (TSX-V:AZX) (OTCQB:ALXDF) (Frankfurt:A9D) (“AZX” or the “Company”) releases a new letter to shareholders outlining the events leading up to the termination of Eric Owens as the Company’s CEO, and warns against his self-interested attempt to take control of AZX.

Alexandria Minerals Announces Support of Eric Sprott and Sprott Inc. for Alexandria’s Director Nominees, New Corporate Direction

2018-06-26 globenewswire
TORONTO, June 26, 2018 (GLOBE NEWSWIRE) -- Alexandria Minerals Corporation (TSX-V:AZX) (OTCQB:ALXDF) (Frankfurt:A9D) (“AZX” or the “Company”) is pleased to announce two of its top shareholders, Eric Sprott and Sprott Inc., are supporting and have committed to vote for the Company’s director nominees at the special meeting of shareholders (the “Meeting”) scheduled for July 24, 2018.

Rebel Capital Inc. Announces Its Qualifying Transaction With Spektra Drilling Canada Inc.

2018-06-14 globenewswire
VANCOUVER, British Columbia, June 14, 2018 (GLOBE NEWSWIRE) -- Rebel Capital Inc. ("Rebel") (TSXV:RBL.P), a capital pool company pursuant to Policy 2.4 of the TSX Venture Exchange (the "TSXV"), is pleased to announce it has entered into a binding amended letter of intent dated June 14, 2018 (the "Letter of Intent") with Spektra Drilling Canada Inc. ("Spektra"), a corporation existing under the laws of Canada.

Updated Resource Contains Approximately 194,500 oz Indicated at 1.61 g/t Gold and 126,300 oz Inferred at 1.89 g/t Gold from Orenada Zones 2 and 4

2018-06-06 globenewswire
TORONTO, June 06, 2018 (GLOBE NEWSWIRE) -- Alexandria Minerals Corporation (TSX-V:AZX) (OTCQB:ALXDF) (Frankfurt:A9D) (“Alexandria” or the “Company”) is pleased to announce that the newly completed mineral resource estimate at Orenada comprises 3,754,000 tonnes of indicated mineral resources with an average grade of 1.61 grams of gold per tonne (“g/t Au”) for 194,522 ounces of contained gold and 2,079,000 tonnes of inferred mineral resources with an average grade of 1.

Alexandria Announces New Corporate Direction

2018-06-06 globenewswire
TORONTO, June 06, 2018 (GLOBE NEWSWIRE) -- Following the results announced today regarding the 2017 drilling plan at Alexandria Minerals Corporation’s (TSX-V:AZX) (OTCQB:ALXDF) (Frankfurt:A9D) (“AZX” or the “Company”) Orenada project undertaken under the direction of former CEO, Eric Owens, who was terminated for cause, the Company is announcing a new corporate direction to build value for all shareholders.

Alexandria Intersects New Gold Zones West of Orenada with up to 1.80 metres @ 36.62 g/t Gold

2018-04-09 globenewswire
TORONTO, April 09, 2018 (GLOBE NEWSWIRE) -- Alexandria Minerals Corporation (TSX-V:AZX) (OTCQB:ALXDF) (Frankfurt:A9D) (“AZX” or the “Company”) is pleased to announce the assay results from the first eight diamond drill holes from it’s 2018 winter drill program on new areas west and north-west of the Company’s Orenada property in Val d’Or, Quebec. For the 2018 winter program the company drilled 34 holes for 12,072.

Alexandria Minerals Sets the Record Straight on Eric Owens’ Termination and Unauthorized Financing Scheme

2018-03-28 globenewswire
TORONTO, March 28, 2018 (GLOBE NEWSWIRE) -- On February 13, 2018, the Board of Alexandria Minerals Corporation (TSX-V:AZX) (OTCQB:ALXDF) (Frankfurt:A9D) (“AZX” or the “Company”) terminated Eric Owens as Chief Executive Officer for cause because, among other things, he engaged in an unauthorized financing scheme and accepted investors’ funds into his personal lawyer’s trust account. These funds were illicitly obtained without the Board’s approval and solicited to a limited network of investors selected by Mr.

Alexandria Minerals Sets Date for Requisitioned Shareholder Meeting

2018-03-16 globenewswire
TORONTO, March 16, 2018 (GLOBE NEWSWIRE) -- Alexandria Minerals Corporation (TSX-V:AZX) (OTCQB:ALXDF) (Frankfurt:A9D) (“AZX” or the “Company”) announces it will hold a special meeting of shareholders (the “Meeting”) on July 24, 2018.

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...